Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937.5 million deal. Suzhou's Kintor Pharma will start a US Phase II trial of its treatment for male pattern baldness. Ascletis Pharma of Hangzhou started a China bridging trial of its FXR agonist f...
Artystarty/iStock via Getty Images Thanks to the prospects of earning a spot in the S&P 500 Index, Moderna (MRNA) jumped ~23.0% this week to breeze past $100B market capitalization. The frontrunner in COVID-19 vaccine development has taken less than three yea...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips FibroGen (NASDAQ: FGEN ) stock is falling hard on Friday after the company received the results of a review for one of its drugs. Source: Bukhta Yurii / Shutterstock.com Those results come in the form of a vot...
The medical community has not been entirely convinced of the U.S. FDA’s decision to approve Biogen Inc’s ( NASDAQ: BIIB ) Aduhelm drug to treat Alzheimer’s last month. Some health insurers also declined coverage for Aduhelm The latest blow to the biotech...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (NASDAQ: MRNA ) stock is on the rise Friday as the company prepares to join the S&P 500 . Source: Shutterstock MRNA stock is set to join the S&P 500 before trading starts on Wednesday . The r...
Chinnapong/iStock via Getty Images A panel convened by the nonprofit Institute of Clinical and Economic Review ("ICER") voted 15-0 that Biogen's ([[BIIB]] -6.8%) Aduhelm (aducanumab) lacks evidence to support its clinical benefit , STAT reports.The vote follows that of an advisory committee t...
When you're evaluating two companies that will compete for the same target market, it's a bit like betting on a boxing match. By judging what each business is capable of before the match starts, keen investors can calculate the odds and pick a profitable bet. Of course, when we're looking a...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It looks like the recent controversy surrounding Biogen (NASDAQ: BIIB ) is not dying down. In fact, bearish attitudes toward the company’s newest drug are seemingly coming back to haunt it. Now, hospitals are t...
travellinglight/iStock via Getty Images In the company’s earnings call today, UnitedHealth ([[UNH]] +1.3%) said it needed more clarity before determining the coverage policy for Aduhelm, the Alzheimer’s drug developed by Biogen ([[BIIB]] -6.7%) and Eisai ([[ESALY]] -4....
News, Short Squeeze, Breakout and More Instantly...
Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing pro...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its first quarter on Wednesday. Biogen reported first-quarter adjusted EPS of $...